Investment Rating - The report assigns an "Accumulate" rating for the company for the first time [1] Core Insights - The company is a leader in the medical sodium hyaluronate dressing market and is actively expanding into class III medical devices [4] - The company has established a diverse product matrix focusing on functional skincare products and class II medical devices, leveraging core technologies of sodium hyaluronate and collagen [16][17] - The online direct sales ratio has been steadily increasing, with significant growth on platforms like Tmall and Douyin [28][33] - The company's stock ownership is highly concentrated, with the chairman holding 84.41% of shares, which enhances operational execution and team stability [34][38] Financial Forecast - The company's total revenue is projected to be 1,823.46 million yuan in 2025, with a year-on-year decline of 9.59%, followed by a recovery to 2,054.34 million yuan in 2026, and 2,259.77 million yuan in 2027 [7][9] - The net profit attributable to shareholders is expected to be 452.41 million yuan in 2025, down 31.57% year-on-year, followed by 502.92 million yuan in 2026 and 539.82 million yuan in 2027 [7][9] - The company's price-to-earnings (P/E) ratios for 2025-2027 are projected to be 27.6, 24.8, and 23.1 times, respectively [7][9] Industry Overview - The professional skincare industry in China has seen significant growth, with the market size for functional skincare products and medical dressings expected to reach 623.0 billion yuan and 253.8 billion yuan by 2026, respectively [52][56] - The market for professional skincare products has grown from 102.5 billion yuan in 2017 to 309.6 billion yuan in 2021, with a compound annual growth rate (CAGR) of 31.8% [52][56] - The competitive landscape in the medical dressing market is fragmented, with the company holding a 10.1% market share, making it the leading brand in the industry [60]

Investment Rating - The report assigns an "Accumulate" rating for the company for the first time [1] Core Viewpoints - The company is a leader in the medical sodium hyaluronate dressing market and is actively expanding its product line to include type III human-derived collagen products [4] - The company has a strong channel advantage, having expanded its medical dressing products from public hospitals to various medical institutions, beauty organizations, and retail pharmacies [9] - The online direct sales ratio has been steadily increasing, from 24.97% in 2020 to an expected 49.67% in 2024, indicating a shift towards e-commerce [9] Financial Forecast - Total revenue is projected to be 1,933.50 million yuan in 2023, with a growth rate of 9.29%, and is expected to reach 2,259.77 million yuan by 2027, with a growth rate of 10.00% [7] - Net profit attributable to the parent company is forecasted to be 749.34 million yuan in 2023, declining to 452.41 million yuan in 2025, before recovering to 539.82 million yuan by 2027 [7] - The company's price-to-earnings (P/E) ratios for 2025-2027 are projected to be 27.6, 24.8, and 23.1 times, respectively [9] Industry Overview - The professional skin care product market in China has grown from 180.5 billion yuan in 2017 to 317.1 billion yuan in 2021, with a compound annual growth rate (CAGR) of 15.1% [48] - The market for functional skin care products and medical dressings is expected to reach 623.0 billion yuan and 253.8 billion yuan, respectively, by 2026 [53] - The competitive landscape in the medical dressing market is fragmented, with the company holding a 10.1% market share, making it the leading brand in the industry [9][61]

Investment Rating - The report gives a "Buy" rating for the company, with a forecasted revenue of 1.791 billion, 2.074 billion, and 2.274 billion yuan for 2025, 2026, and 2027 respectively, and a net profit of 451 million, 524 million, and 576 million yuan for the same years [3]. Core Insights - The company has established a strong position in the medical dressing market through 30 years of development, focusing on high-quality growth and transformation [2][7]. - The company has built a comprehensive product matrix and sales channels, leveraging its first-mover advantage in the professional repair sector [2][3]. - The outlook for the company is positive, with expectations for long-term high-quality growth driven by product expansion and channel optimization [3]. Company Overview - Founded in 1996 as Huaxin Pharmaceutical, the company transitioned to skincare products in 2012 and established itself as a leading player in the medical beauty skincare sector [7][10]. - The company has undergone significant changes, including the establishment of a Shanghai R&D center and a Hangzhou operational subsidiary, to enhance its development towards high-quality growth [3][14]. - The management team, led by founder Zhang Liguo, has extensive experience in the pharmaceutical and skincare industries, ensuring strategic continuity and effective execution of growth plans [14][16]. Industry Overview - The professional skincare market is rapidly expanding, with the medical dressing segment expected to grow significantly due to increasing consumer awareness and demand for effective skincare solutions [42][44]. - The medical dressing market is projected to reach 253.8 billion yuan by 2026, with a growth rate of 22.08%, driven by the rising demand for post-surgical and skin repair products [44][45]. - The market for patch-type products is also expected to grow, with a forecasted size of 271.8 billion yuan by 2026, reflecting a 17.05% growth rate [44][46].

Group 1: Sales and Financial Goals - The financial data for Q4 2025 is still under audit, with specific sales figures to be disclosed in the annual report on April 23, 2026 [2] - The company aims to enhance both online and offline sales, leveraging R&D advantages and improving product offerings to boost profitability [2] Group 2: Product Structure and Development - The current product structure includes medical devices and functional skincare products, with various forms such as patches and non-patch products [3] - The company plans to introduce new products in 2026 across both categories, including dressings, masks, and various skincare formulations [3] Group 3: R&D and Innovation - The company employs a "North-South linkage + internal-external collaboration" R&D model, with dedicated centers in Shanghai and Harbin [3] - Collaboration with third-party research institutions is aimed at expanding research directions and enhancing R&D efficiency [3] Group 4: Sales Channel Optimization - The offline sales channel optimization is progressing as expected, focusing on transitioning to a value-driven sales model [4] - The strategy includes meticulous inventory management and dynamic price monitoring to prevent stockpiling risks [4] Group 5: Regulatory and Product Registration - In 2025, the company registered two new cosmetic ingredients: Feruloyl Tripeptide-129 Amide and Acetyl Dipeptide-110 Amide [4] - The company holds four Class II medical device registrations, including products like medical sodium hyaluronate repair patches [4] Group 6: Business Expansion and Investor Relations - The company is monitoring potential mergers and acquisitions but currently has no suitable targets [6] - The dividend plan for 2025 is yet to be determined, depending on the company's performance and funding plans for 2026 [6]

Core Viewpoint - The company has received approval for four Class II medical device registration certificates, indicating progress in its product development and regulatory compliance [1] Group 1 - The company has obtained approval for four medical device registration certificates [1] - The approved products include: medical sodium hyaluronate repair patch, medical sodium hyaluronate repair solution, medical recombinant type III humanized collagen patch, and medical trehalose repair patch [1]

Group 1: Company Overview - Fulejia is a professional skin care product company focused on R&D, production, and sales of medical devices and functional skin care products, with a multi-channel sales strategy that includes both online and offline platforms [2][3]. - The company has established a comprehensive market reach through major e-commerce platforms like Tmall, Douyin, JD.com, and Pinduoduo, as well as offline channels including specialty cosmetics stores, large supermarkets, chain pharmacies, beauty institutions, and medical facilities [2]. Group 2: Product Registration and R&D - Fulejia has obtained 4 Class II medical device registrations, including products such as medical sodium hyaluronate repair patches and medical recombinant type III humanized collagen patches [3]. - The company has two R&D centers located in Shanghai and Harbin, focusing on raw material development and medical device product R&D, respectively [3]. - In 2025, Fulejia registered 48 cosmetic products, covering various forms such as water, lotion, cream, and essence [4]. Group 3: Clinical Trials and Product Development - The clinical trial for the recombinant type III humanized collagen freeze-dried fiber project has been completed, and the company is preparing the clinical trial summary report for registration submission [4]. - In 2025, the company completed the registration of two new raw materials, which will be developed into products to enhance the product matrix [3]. Group 4: Channel Optimization and Management - The company is optimizing its offline channels, focusing on sales channel and retail terminal improvements, with financial feedback showing some lag [4][5]. - Future strategies include strengthening partnerships with service-oriented distributors and implementing a dual approach of "strong supervision + strong optimization" to enhance market control and stabilize pricing [5]. Group 5: Management and Shareholding - Currently, there is no intention for the company's directors and senior management to reduce their holdings [5].

Core Viewpoint - The company Hasi Lian (002900.SZ) is expected to report a net loss of over 315 million to 375 million yuan for the year 2025, marking its first annual loss since its listing in 2017, primarily due to declining sales prices, increased operating costs, and significant credit impairment losses [3][4][5]. Financial Performance - Hasi Lian's projected net profit loss for 2025 is between 315 million and 375 million yuan, representing a year-on-year decline of 636.85% to 739.11% [6]. - The company's revenue is expected to drop to 790 million yuan, a decrease of 30% compared to the previous year [7]. - The basic earnings per share are projected to be in the range of -1.19 to -1.00 yuan [6]. Cost and Expense Analysis - The company anticipates an increase in operating costs and expenses, with sales expenses expected to rise by over 23.5 million yuan due to increased investments in the health sector [7]. - Depreciation expenses are projected to increase by over 31 million yuan, primarily due to the completion of construction projects [7]. - The company will also incur significant inventory impairment losses of nearly 38 million yuan due to declining net realizable value of certain inventories [7][8]. Business Transition Challenges - Hasi Lian's traditional pharmaceutical business is under pressure, and its transition to animal health and wellness sectors has not yet yielded significant results [10][12]. - The pharmaceutical segment, which constitutes over 86% of total revenue, has seen a decline in sales revenue, dropping by 24.25% year-on-year in the first half of 2025 [11][12]. - The gross margin of the pharmaceutical business has been declining, from 69.72% in 2021 to 55.34% in 2024 [12]. Strategic Developments - Hasi Lian has been attempting to diversify into animal health and wellness sectors, but these segments accounted for only 3.65% of total revenue in the first half of 2025 [12]. - The company has participated in industry exhibitions to promote its new products in the beauty and health sectors, indicating a strategic shift [12][13]. - Hasi Lian has also planned to sell a portion of its stake in its subsidiary, Fulejia, within 24 months, reflecting ongoing adjustments in its investment strategy [14].

Core Viewpoint - The company, Harbin Sanlian (哈三联), is facing significant financial challenges, with an expected net loss of 315 million to 375 million yuan for the fiscal year 2025, marking its first annual loss since its listing in 2017 [1][2]. Financial Performance - The projected net loss for 2025 represents a year-on-year decline of 636.85% to 739.11% compared to the previous year, with a basic earnings per share expected to be between -1.19 yuan and -1 yuan [2]. - The company's revenue for 2025 is anticipated to be 790 million yuan, a decrease of 30% or 343 million yuan from the previous year [3]. Causes of Decline - The decline in performance is attributed to several factors, including a drop in sales prices due to national drug procurement policies and increased competition in the market [3]. - The company has reported a significant increase in operating costs and expenses, with sales expenses expected to rise by over 23.5 million yuan, primarily due to investments in the health sector [3]. - A substantial credit impairment loss of 24.626 million yuan has been recognized, primarily related to two counterparties [4]. Business Transition - The traditional pharmaceutical business of the company is under pressure, and its transition into animal health and wellness sectors has not yet yielded effective financial support [5]. - The pharmaceutical segment remains the core business, contributing over 86% of total revenue, but has seen a continuous decline in revenue and gross margin [6][7]. Market Position and Strategy - The company has made efforts to diversify into animal health and wellness, but these segments currently contribute only a small fraction (approximately 3.65%) of total revenue [7]. - Harbin Sanlian has participated in industry exhibitions to promote its cosmetic and medical products, indicating a strategic shift towards beauty and health markets [7]. Shareholding and Investments - As of the third quarter of 2025, the company still holds a 4.5% stake in Fulejia (敷尔佳), which is currently the only profitable investment among its subsidiaries [8].

Core Viewpoint - Fulejia, known as the "first stock of medical beauty masks," is facing significant challenges, with a reported revenue decline of 11.54% year-on-year for the first three quarters of 2025, totaling 1.297 billion yuan. The company aims to achieve at least 700 million yuan in revenue in the fourth quarter, which appears to be a considerable challenge [2]. Group 1: Business Performance and Challenges - Fulejia's revenue for the full year of 2024 was 2.017 billion yuan, indicating a need for substantial growth in Q4 2025 to meet targets [2]. - The company's medical device product revenue share has decreased from 55.54% in 2020 to 42.28% in 2024, and further down to 27.61% in the first half of 2025, highlighting a significant impact on its financial performance [9]. - The tightening of regulations regarding "medical beauty masks" has created a clearer distinction between medical devices and cosmetic products, further complicating Fulejia's market position [6][7]. Group 2: Product Development and Market Strategy - Fulejia has made progress in its Class III medical device projects, with a new product, "recombinant type III humanized collagen dressing," entering clinical stages, while other products are in various stages of development [2][4]. - The shift towards Class III medical devices is part of a broader trend among beauty brands, as many are moving away from Class II products due to market saturation and regulatory challenges [3][4]. - Fulejia's entry into the Class III market is seen as a strategy to strengthen its position in the medical beauty sector, although it is currently lagging behind competitors who have already secured Class III registrations [4]. Group 3: Transition to Cosmetics - Fulejia's cosmetics business has seen growth, with revenue surpassing that of medical devices for the first time in 2022, indicating a strategic pivot [11]. - However, the brand still faces challenges in changing consumer perceptions from a medical mask brand to a cosmetics brand, as many consumers associate Fulejia primarily with medical beauty masks [12]. - The company has encountered complaints regarding its cosmetic products, raising concerns about safety and efficacy, which could hinder its ability to attract new customers [12]. Group 4: Research and Development - Fulejia's R&D investment for the first three quarters of 2025 was 36.31 million yuan, with a R&D expense ratio of 2.8%, which, while improved, remains low compared to competitors [14]. - The company holds a total of 61 patents, but the majority are design patents, indicating a potential weakness in innovation compared to peers in the beauty industry [14]. - Balancing R&D investments between medical devices and cosmetics presents a challenge for Fulejia, as both sectors require significant resources to remain competitive [16].

Core Viewpoint - The company Fulejia, known as the "first stock in medical beauty masks," has reported a significant decline in both revenue and net profit for the first half of 2025, marking its worst performance since going public [2][3]. Financial Performance - The company's revenue decreased by 8.15% to 863 million yuan, down from 940 million yuan in the same period of 2024, marking the first negative growth in half-year revenue since its listing [2][3]. - Net profit fell by 32.54% to 230 million yuan, down from 341 million yuan year-on-year, with non-recurring net profit nearly halved, dropping by 48.66% [2][3]. - In Q1 2025, revenue was 301 million yuan, a significant decline of 26.39%, while net profit was 91 million yuan, down 39.77% [3]. - Q2 2025 saw revenue of 562 million yuan, a slight increase of 5.9%, primarily driven by online promotions of cosmetic products, but net profit still declined by 26.72% to 138 million yuan [3][4]. Cost Structure and Profitability - Sales expenses surged to 420 million yuan in the first half of 2025, a year-on-year increase of 39.56%, accounting for 48.67% of total revenue [4][8]. - The gross margin for cosmetic products decreased by 1.11 percentage points to 80.42%, despite a revenue increase of 29.95% to 625 million yuan [7][8]. - Medical device product revenue plummeted by 48.07% to 238 million yuan, significantly impacting overall profitability [5][6]. Market and Regulatory Environment - New regulations from the National Medical Products Administration in 2025 require greater transparency in raw material safety information, increasing compliance costs for medical beauty companies [7]. - The company faces challenges from increased regulatory scrutiny and a competitive market, which has led to a decline in consumer trust due to over-promotional practices [7][11]. Strategic Recommendations - Experts suggest that the company should enhance R&D investment to improve product innovation and diversify its distribution channels, particularly by strengthening partnerships with offline medical beauty institutions [11]. - There is a need for the company to shift its focus from heavy marketing expenditures to building a robust product development strategy to regain market confidence and ensure long-term sustainability [11].